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Circulating levels of the endogenous inhibitor of nitric oxide synthase, asymmetric dimethy-
larginine (ADMA), are positively associated with the prevalence of metabolic syndrome
(MetS) in cross-sectional investigations. It is unclear if circulating ADMA and other methylar-
ginines are associated with incident MetS prospectively.
Methods
We related circulating ADMA, symmetric dimethylarginine (SDMA), L-arginine (ARG) con-
centrations (measured with a validated tandem mass spectrometry assay) and the ARG/
ADMA ratio to MetS and its components in 2914 (cross-sectional analysis, logistic regres-
sion; mean age 58 years, 55% women) and 1656 (prospective analysis, Cox regression;
mean age 56 years, 59% women) individuals from the Framingham Offspring Study who
attended a routine examination.
Results
Adjusting for age, sex, smoking, and eGFR, we observed significant associations of ADMA
(direct) and ARG/ADMA (inverse) with odds of MetS (N = 1461 prevalent cases; Odds Ratio
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[OR] per SD increment 1.13, 95%CI 1.04–1.22; and 0.89, 95%CI 0.82–0.97 for ADMA and
ARG/ADMA, respectively). Upon further adjustment for waist circumference, systolic and
diastolic blood pressure, glucose, high-density lipoprotein cholesterol, and triglycerides, we
observed a positive relation between SDMA and MetS (OR per SD increment 1.15, 95% CI
1.01–1.30) but the other associations were rendered statistically non-significant. We did not
observe statistically significant associations between any of the methylarginines and the risk
of new-onset MetS (752 incident events) over a median follow-up of 11 years.
Conclusion
It is unclear whether dimethylarginines play an important role in the incidence of cardiometa-
bolic risk in the community, notwithstanding cross-sectional associations. Further studies of
larger samples are needed to replicate our findings.
Introduction
Insulin resistance (IR) is a key component of the metabolic syndrome (MetS), which is character-
ized by abdominal obesity, impairment of fasting glucose, dyslipidemia, and hypertension [1, 2].
Individuals with MetS are at increased risk of developing type 2 diabetes and cardiovascular dis-
ease [3–6], presumably because these people have IR and a higher burden of subclinical athero-
sclerosis [7]. It is well established that impaired endothelial nitric oxide (NO) production, often a
mediator of endothelial dysfunction, is an early step during the development of atherosclerosis
and vascular disease [8, 9]. In this context, the endogenous inhibitor of nitric oxide synthase
(NOS), asymmetric dimethylarginine (ADMA), has emerged as an independent predictor for
vascular disease and mortality [10]. Endothelial dysfunction and ADMA have also been reported
to be associated with IR in hypertensive patients [11, 12], and each of the individual components
of the MetS has been associated with impaired endothelial function [5, 6, 13]. Consistent with
these observations, mice with a genetic disruption of endothelial NOS display hyperlipidemia,
hypertension, and IR, whereas mice overexpressing human dimethylarginine dimethylaminohy-
drolase 1 (DDAH1), the enzyme mainly responsible for degrading ADMA, show increased insu-
lin sensitivity [14, 15]. Therefore, we hypothesized that ADMA-mediated NOS inhibition might
be involved in the pathogenesis of cardiometabolic risk. However, although individuals with
MetS have higher circulating ADMA levels compared to individuals without MetS in some
cross-sectional studies [16–18], to date, no prior investigation has examined the association
between ADMA and the incidence of MetS prospectively. Furthermore, very little is known
about the association of symmetrical dimethylarginine (SDMA) with cardiometabolic risk
because SDMA (which does not directly inhibit NOS) was thought to be biologically inert.
Recently, studies have shown SDMA exerts its biological effects by inhibiting cationic amino
acid transport into cells leading to limited cellular L-arginine (ARG) uptake [19–21]. Nonethe-
less, it was shown that SDMA is inversely related to IR in healthy individuals, and with glycemic
control in patients with diabetes [22–26]. In order to further elucidate the relations between
dimethylarginines and the development of metabolic disease, we investigated the associations of
circulating ADMA, SDMA, ARG, and the ARG/ADMA ratio with prevalent and incident MetS
in the large, community-based Framingham Offspring Study sample. We hypothesized that
higher and lower plasma concentrations of ADMA and ARG, respectively, are associated with
higher odds of MetS cross-sectionally and with a higher risk of MetS prospectively.
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Methods
Study sample
The design and enrollment criteria of the Framingham Offspring Study have been described
in detail elsewhere [27]. The present investigation evaluated two samples of the Offspring
cohort obtained from attendees at their sixth quadrennial examination cycle (1995–1998): one
sample for the cross-sectional analysis of dimethylarginines with prevalent MetS, and another
sample for the prospective relations of dimethylarginines and incident MetS.
For the cross-sectional analysis, 3532 participants were eligible and 618 individuals were
excluded for the following reasons: prevalent cardiovascular disease (coronary heart disease,
cerebrovascular disease, intermittent claudication or congestive heart failure; n = 413), serum
creatinine >2mg/dL (n = 8), eGFR>150mL/min per 1.73 m2 (n = 52), triglycerides > 400
mg/dL (n = 36), missing data on components of MetS (n = 63), missing data on dimethylargi-
nines (n = 22), missing data on covariates (n = 24), resulting in a sample size of 2914 partici-
pants (Sample 1) for the cross-sectional analyses (Fig 1).
Sample 2, which was used for prospective analyses, was nested within Sample 1. From the
2914 individuals in Sample 1, we additionally excluded participants with prevalent MetS at
exam 6 (n = 1143), those who did not attend at least one of the subsequent examinations 7
(1998–2001), 8 (2005–2008) or 9 (2011–2014) (n = 77), and those who were missing compo-
nents of MetS upon follow-up (n = 38). After exclusions, the final sample consisted of 1656
participants for the prospective analysis (Sample 2; Fig 1). The study protocol was approved by
the Institutional Review Board at Boston University Medical Center and all participants pro-
vided written informed consent.
Assessment of clinical variables and biomarkers of interest
Participants underwent standardized examinations at the Framingham Heart Study research
center during which a medical history, a targeted physical examination, anthropometric mea-
surements, and laboratory assessment of cardiovascular risk factors were conducted. Fasting
blood samples were obtained from the participants after five to ten minutes rest in a supine
position. Plasma samples from the sixth examination cycle, which had been stored without
freeze-thaw cycles at -80˚C, were used for the measurement of dimethylarginines (ADMA,
SDMA) and ARG by liquid chromatography-tandem mass spectrometry (LC-MS/MS) using a
stable isotope dilution assay as previously described [28–30].
Assessment of metabolic syndrome
Prevalent and incident MetS were defined as binary variables according to the modified defini-
tion of the National Cholesterol Education Program Adult Treatment Panel guidelines [1].
Participants were classified as having MetS if�3 of the following criteria were met: abdominal
obesity (waist circumference in men�102 cm, in women�89 cm), elevated blood pressure
(systolic�130 mmHg or diastolic�85 mmHg) or use of antihypertensive medication; elevated
fasting glucose (�100 mg/dl) or use of anti-hyperglycemic medication; elevated triglycerides
(�150 mg/dl) or use of lipid-lowering treatment; or low HDL cholesterol (men <40 mg/dl,
women <50 mg/dl).
Statistical analysis
Using sample 1, we examined the cross-sectional associations of ADMA, SDMA, ARG, and
the ARG/ADMA ratio (independent variables, separate model for each) with the presence of
MetS (dependent variable) using two multivariable logistic regression models. The first model
PLOS ONE ADMA, SDMA, and the metabolic syndrome
PLOS ONE | https://doi.org/10.1371/journal.pone.0254577 September 7, 2021 3 / 12
Fig 1. Sample exclusion diagram.
https://doi.org/10.1371/journal.pone.0254577.g001
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was adjusted for age, sex, smoking, and eGFR. The second model additionally included waist
circumference, systolic and diastolic blood pressure, fasting glucose, high-density lipoprotein
cholesterol, and triglycerides. To evaluate potential nonlinear associations between each of the
biomarkers and prevalence of the MetS, we created restricted cubic spline plots with 3 knots at
the 10th, 50th, and 90th percentiles [31].
Next, we evaluated the associations of ADMA, SDMA, ARG, and ARG/ADMA (indepen-
dent variables, separate model for each) with the incidence of new-onset MetS (absence of MetS
at examination cycle 6 and presence of MetS at any of examination cycles 7, 8, or 9) using Cox
regression models with discrete time intervals, with examination cycle 6 serving as the baseline,
adjusting for the same covariates listed above. We created restricted cubic splines to evaluate
potential nonlinear associations between each biomarker and incident MetS. Statistical signifi-
cance was assessed based on a Bonferroni-adjusted two-sided p-value of<0.0125 (0.05 divided
by 4 [= number of methylarginine biomarkers evaluated]). The SAS Software version 9.4 (Cary,
NC) was used for all analyses. The authors had full access to the data and take responsibility for
its integrity. All authors have read and agree to the manuscript as written.
Results
Baseline characteristics
The baseline characteristics of the cross-sectional and prospective study samples (samples 1
and 2, respectively) are displayed in Table 1. More than half of the participants of the cross-
sectional sample displayed abdominal obesity or elevated blood pressure.
Cross-sectional association of ADMA, SDMA, ARG, and ARG/ADMA with
prevalent metabolic syndrome
Higher ADMA and lower ARG/ADMA concentrations were associated with higher odds of
prevalent MetS, adjusting for age, sex, smoking, and eGFR, but further adjustment for waist
circumference, systolic and diastolic blood pressure, glucose, high-density lipoprotein (HDL)
cholesterol, and triglycerides rendered the associations statistically non-significant. SDMA was
not associated with MetS when adjusting for age, sex, smoking, and eGFR, but further adjust-
ment for the covariates listed above rendered the association statistically significant (Table 2).
Examination of restricted cubic spline plots did not show significant non-linear associations
(S1 Fig).
Prospective association of ADMA, SDMA, ARG, and ARG/ADMA with
incident metabolic syndrome
During a median follow-up of 11 years, 752 individuals developed new-onset MetS (Table 3).
We did not observe a statistically significant association between any of the methylarginine
biomarkers and risk of developing new-onset MetS. As with cross-sectional analyses, examina-
tion of restricted cubic spline plots did not show significant non-linear associations between
biomarkers and incident MetS (S2 Fig).
Discussion
Principal findings
Cross-sectionally, higher ADMA and lower ARG/ADMA were associated with higher odds of
prevalent MetS adjusting for age, sex, smoking, and eGFR, but further adjustment for addi-
tional covariates rendered these associations statistically non-significant. Of note, SDMA was
PLOS ONE ADMA, SDMA, and the metabolic syndrome
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not associated with odds of MetS in minimally-adjusted models (adjusting for age, sex, smok-
ing, and eGFR), but the association became significant in fully-adjusted models.
Table 1. Characteristics of study participants at the baseline examination for the cross-sectional and prospective analyses.
Cross-sectional sample Prospective sample
Men (n = 1310) Women (n = 1604) Men (n = 683) Women (n = 973)
Clinical characteristics
Age, years 58 ± 10 58 ± 10 56 ± 10 56 ± 9
Smoking, N (%) 185 (14) 237 (15) 97 (14) 141 (15)
Hypertension, N (%) 534 (41) 565 (35) 167 (24) 183 (19)
Diabetes, N (%) 115 (9) 100 (6) 17 (2) 5 (0.5)
Metabolic Syndrome, N (%) 568 (43) 575 (36) N/A N/A
Abdominal obesity, N (%) 607 (46) 961 (60) 180 (26) 401 (41)
Elevated BP, N (%) 766 (58) 768 (48) 268 (39) 277 (28)
Elevated triglycerides, N (%) 475 (36) 515 (32) 89 (13) 113 (12)
Low HDL cholesterol, N (%) 493 (38) 483 (30) 112 (16) 133 (14)
Elevated fasting glucose, N (%) 653 (50) 493 (31) 212 (31) 96 (10)
Laboratory Values
BMI, kg/m2 28.5 ± 4.4 27.2 ± 5.6 27.0 ± 3.7 25.2 ± 4.2
Waist circumference, cm 101 ± 11 94 ± 15 97 ± 9 88 ± 12
SBP, mmHg 130 ± 17 126 ± 20 124.4 ± 16.0 120 ± 17
DBP, mmHg 78 ± 9 74 ± 9 75.9 ± 8.6 72 ± 9
Fasting glucose, mg/dL 105 ± 24 99 ± 23 98.6 ± 17.3 91 ± 9
Triglycerides, mg/dL 131 ± 68 125 ± 64 104 ± 48 100 ± 48
Total cholesterol, mg/dL 200 ± 35 211 ± 38 200 ± 34 207 ± 38
HDL cholesterol, mg/dL 45 ± 12 59 ± 16 49 ± 12 64 ± 15
eGFR, mL/min 87 ± 17 85 ± 19 87 ± 16 87 ± 18
ADMA, μmol/L 0.55 ± 0.12 0.54 ± 0.13 0.54 ± 0.12 0.53 ± 0.13
SDMA, μmol/L 0.40 ± 0.10 0.39 ± 0.09 0.40 ± 0.09 0.38 ± 0.09
L-arginine, μmol/L 79.8 ± 21.1 77.9 ± 20.4 79.5 ± 20.6 78.4 ± 21.2
Arg/ADMA 150.6 ± 45.3 149.2 ± 43.8 152.4 ± 44.7 152.9 ± 44.0
Data are displayed as means ± standard deviation or frequency and percent (parentheses). Hypertension is defined as SBP/DBP of �140/90 or use of anti-hypertension
medication. Abdominal obesity is defined among men as a waist circumference�102 cm, and among women as a waist circumference�89 cm. Elevated BP is defined
as SBP/DBP� 130/85 or use of anti-hypertension medication. Elevated triglycerides are defined as�150 mg/dL or use of lipid-lowering medication. Low HDL is
defined as <40mg/dL for men and <50mg/dL for women. Elevated fasting glucose is defined as fasting glucose�100mg/dL or use of anti-hyperglycemic medication.
https://doi.org/10.1371/journal.pone.0254577.t001
Table 2. Association of biomarkers with prevalent metabolic syndrome.
Model 1 Model 2
Biomarker OR (95% CI) p-value OR (95% CI) p-value
ADMA 1.13 (1.04, 1.22) 0.002 1.08 (0.96, 1.22) 0.19
SDMA 0.94 (0.87, 1.02) 0.16 1.15 (1.01, 1.30) 0.032
L-Arginine 0.97 (0.90, 1.05) 0.45 1.05 (0.94, 1.17) 0.39
ARG/ADMA 0.89 (0.82, 0.97) 0.004 0.99 (0.89, 1.11) 0.92
Data are displayed as odds ratios (95% confidence intervals) per 1 standard deviation increase in the respective
biomarker.
Model 1 is adjusted for age, sex, smoking, and eGFR.
Model 2 includes the adjustment variables in Model 1 plus waist circumference, SBP, DBP, glucose, HDL cholesterol,
and triglycerides.
https://doi.org/10.1371/journal.pone.0254577.t002
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Experimental evidence for NOS-inhibition in metabolic disease
Experimental evidence connects impairment of endothelial NO production with metabolic
disturbances. Apart from the associations of the genetic models of the eNOS knockout mice
and the DDAH1 transgenic mice with insulin sensitivity noted earlier [14, 15], it has been
shown that infusion of the NOS-inhibitor N-monomethyl L-arginine (L-NMMA) in rats
induced hypertension and insulin-resistance [32]. Moreover, infusion of ADMA into C57BL/6
and apolipoproteinE (ApoE) knockout mice increased plasma triglycerides [33]. Furthermore,
there are additional experimental data supporting a causal relation between NOS inhibition
and IR. In an experimental setting it was observed that insulin-mediated glucose uptake is
closely connected to insulin-mediated, NOS-dependent vasodilation and microvascular
recruitment, which in turn are attenuated by NOS-inhibition [34–36]. Moreover, a non-obese
IR rat model fed with fructose showed an elevation of circulating and aortic ADMA concentra-
tions, as well as reduced DDAH aortic content and increased aortic arginase activity in IR.
Likewise, ARG supplementation and arginase inhibition improve endothelial vasodilatation in
IR rats providing further functional corroboration [2].
Comparison to the literature
ADMA and MetS. Several cross-sectional investigations have analyzed ADMA plasma
levels in people with MetS while others evaluated the associations of ADMA plasma levels with
individual components of MetS. Recent prospective studies have related plasma dimethylargi-
nines to the risk of developing MetS but their findings are not consistent [24–26, 37–39]. Sev-
eral studies reported that plasma ADMA was not significantly higher in people with MetS [19–
21, 40], although the literature has not been entirely consistent in this regard [16–18]. Further-
more, plasma ADMA concentrations have also been directly related to measures of IR such as
the homeostasis model assessment (HOMA), insulin suppression test or hyperinsulinemic,
and euglycemic clamp in non-diabetic individuals, including healthy people as well as obese,
elderly and hypertensive individuals [2, 41–43]. Clinical studies also have reported higher
ADMA plasma concentrations with higher values of anthropometric measures of excess adi-
posity such as body mass index (BMI), waist circumference, body fat mass, and body weight in
healthy individuals [44, 45]. This relation between ADMA, obesity, and IR is further supported
by interventional studies, which have shown that weight loss was associated with a lowering of
circulating ADMA levels in obese individuals, which in turn was accompanied by an increase
in insulin sensitivity and NO production [46, 47]. Contrary to these findings, our prospective
investigation showed no statistically significant association between ADMA and risk of
Table 3. Association of biomarkers with incident metabolic syndrome.
Model 1 Model 2
Biomarker HR (95% CI) p-value HR (95% CI) p-value
ADMA 1.02 (0.94, 1.11) 0.61 1.02 (0.94, 1.12) 0.63
SDMA 0.94 (0.86, 1.02) 0.14 1.04 (0.95, 1.14) 0.37
L-Arginine 1.01 (0.93, 1.10) 0.80 1.02 (0.94, 1.11) 0.63
ARG/ADMA 1.00 (0.92, 1.08) 0.94 1.02 (0.93, 1.10) 0.73
Data are displayed as hazard ratios (95% confidence intervals) per 1 standard deviation increase in the respective
biomarker.
Model 1 is adjusted for age, sex, smoking, and eGFR.
Model 2 includes the adjustment variables in Model 1 plus waist circumference, SBP, DBP, glucose, HDL cholesterol,
and triglycerides.
https://doi.org/10.1371/journal.pone.0254577.t003
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developing new-onset MetS. Furthermore, the attenuation of the cross-sectional association
we observed between ADMA and presence of MetS could be due to the fact that we adjusted
the model for variables that are components of the MetS.
SDMA and MetS. SDMA has been less well investigated, but there is increased focus with
regards to its relation with cardiometabolic diseases. SDMA was inversely associated with the
HOMA index in a sample of healthy white individuals [22]. In another report evaluating
patients with type 2 diabetes, plasma SDMA levels were inversely associated with glycemic
control [23]. Marliss and colleagues reported that, similar to ADMA, plasma SDMA levels
were positively related with IR and triglycerides, and inversely related with HDL cholesterol
[42]. In our investigation, we observed a direct association of SDMA with prevalent but not
incident MetS, which is consistent with some prior reports [19–21, 25, 26]. Moreover, SDMA
was related to MetS cross-sectionally in a fully-adjusted model but not a minimally adjusted
model, perhaps suggesting the presence of reverse confounding by HDL [48, 49].
The mechanisms by which SDMA exerts its biological effects is by inhibiting cationic
amino acid transport into cells leading to limited cellular l-arginine uptake [19–21]. Addition-
ally, there are some experimental studies connecting SDMA to inflammation and oxidative
stress [50, 51], but additional prospective studies are needed to elucidate how SDMA may be
directly related to the development of metabolic disturbances.
Strengths and limitations
The strengths of our investigation include its design with both cross-sectional and prospective
components, and the large community-based and well-phenotyped sample. Furthermore, the
routine assessment of clinical and laboratory data, including validated assays for dimethylargi-
nines, enabled us to perform multivariable analysis adjusting for relevant covariates. However,
our sample consisted predominantly of white, middle-aged individuals, so our results may not
be generalizable to other races and ethnicities. Moreover, it is possible that dimethylarginine
concentrations fluctuated between exam 6 and the time when assessment of incident metabolic
syndrome was performed; however, dimethylarginines were only measured at examination
cycle 6, therefore we are not able to account for such fluctuations.
Conclusions
In our investigation of a large prospective, community-based sample, it is not clear whether
dimethylarginines play an important role in the pathogenesis of cardiometabolic risk in the
community.
Supporting information
S1 Fig. Association between biomarkers and prevalent metabolic syndrome: Restricted
cubic spline plots.
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